Treatment of cancer cells bearing an amplified, constitutively active MET oncogene with the MET kinase inhibitor JNJ-38877605 (indicated JNJ-605) blocks proliferation in vitro and halts tumour growth in vivo1,27–30. This evidence concerns the gene MET and neoplasm.